Literature DB >> 10604960

Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats.

T Hirano1, Y Yamamura, S Nakamura, T Onogawa, T Mori.   

Abstract

This study was conducted to characterize the diuretic effect of OPC-41061, a nonpeptide vasopressin V(2)-receptor antagonist, and furosemide by administering each alone and in combination in conscious male rats. OPC-41061 at 1 and 10 mg/kg and furosemide at 10 and 100 mg/kg dose-dependently increased urine volume to the same extent. The high dose of OPC-41061 (10 mg/kg) markedly elevated electrolyte-free water clearance (E-CH(2)o) to a positive value. In contrast to OPC-41061, furosemide elevated only electrolyte clearance but not E-CH(2)o. The differences in diuretic profile reflected the changes in serum sodium and hormone levels. OPC-41061 dose-dependently elevated serum sodium concentration, but furosemide tended to decrease it. The high dose of furosemide (100 mg/kg) significantly elevated serum renin activity and aldosterone concentration, indicating that furosemide activated the renin-angiotensin-aldosterone system (RAA-system). On the other hand, OPC-41061 did not affect these parameters. When OPC-41061 was administered concomitantly with furosemide, OPC-41061 significantly increased urine volume and E-CH(2)o, and decreased urinary osmolality compared with furosemide alone. OPC-41061 dose-dependently elevated serum osmolality and sodium concentration even when administered in combination with the high dose of furosemide. These results suggest that OPC-41061 produces aquaresis leading to increased serum sodium without affecting the RAA-system. On the other hand, furosemide produced natriuresis, leading to decreased serum sodium level and activation of the RAA-system. It was also demonstrated that OPC-41061 produced an additive diuretic effect and elevated serum sodium level in the presence of furosemide.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10604960

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  21 in total

1.  Acute effects of the anti-inflammatory cyclooxygenase-2 selective inhibitor, flosulide, on renal plasma flow and glomerular filtration rate in rats.

Authors:  A Turull; C Piera; J Queralt
Journal:  Inflammation       Date:  2001-04       Impact factor: 4.092

2.  Predictability of tricuspid annular plane systolic excursion for the effectiveness of tolvaptan in patients with heart failure.

Authors:  Toru Niwa; Katsuhisa Waseda; Tomofumi Mizuno; Yusuke Nakano; Kentaro Mukai; Hirokazu Wakabayashi; Atsushi Watanabe; Hirohiko Ando; Hiroaki Takashima; Tetsuya Amano
Journal:  J Echocardiogr       Date:  2017-02-13

3.  Two autosomal dominant polycystic kidney (ADPKD) cases with advanced renal dysfunction, effectively treated with tolvaptan.

Authors:  Hirayasu Kai; Yuki Shinozaki; Airi Nishikubo; Megumi Watanabe; Takashi Tawara; Mamiko Iwase; Ryouya Tsunoda; Noriaki Moriyama; Toshiaki Usui; Tetsuya Kawamura; Kei Nagai; Masahiro Hagiwara; Chie Saito; Naoki Morito; Joichi Usui; Kunihiro Yamagata
Journal:  CEN Case Rep       Date:  2015-11-17

4.  Tolvaptan increases urine and ultrafiltration volume for patients with oliguria undergoing peritoneal dialysis.

Authors:  Tohru Iwahori; Masatoshi Esaki; Hayao Hinoue; Shinga Esaki; Yukumi Esaki
Journal:  Clin Exp Nephrol       Date:  2013-10-11       Impact factor: 2.801

5.  Predictive value of the efficacy of tolvaptan in liver cirrhosis patients using free water clearance.

Authors:  Hisamitsu Miyaaki; Yutaka Nakamura; Tatsuki Ichikawa; Naota Taura; Satoshi Miuma; Hidetaka Shibata; Takuya Honda; Kazuhiko Nakao
Journal:  Biomed Rep       Date:  2015-09-28

Review 6.  Pharmacology of vasopressin antagonists.

Authors:  Lisa C Costello-Boerrigter; Guido Boerrigter; John C Burnett
Journal:  Heart Fail Rev       Date:  2008-09-03       Impact factor: 4.214

7.  Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats.

Authors:  Tadashi Okada; Toshifumi Sakaguchi; Ikuji Hatamura; Fumie Saji; Shigeo Negi; Haruhisa Otani; Yasuteru Muragaki; Hiroshi Kawachi; Takashi Shigematsu
Journal:  Clin Exp Nephrol       Date:  2009-05-19       Impact factor: 2.801

Review 8.  Treating hyponatremia in heart failure.

Authors:  Steven R Goldsmith
Journal:  Curr Cardiol Rep       Date:  2006-05       Impact factor: 2.931

9.  Arginine vasopressin antagonist tolvaptan in the treatment of heart failure: a meta-analysis of randomized controlled trials.

Authors:  Chao-Jun Yang; Jun Yang; Jian Yang; Zhi-Xing Fan
Journal:  Int J Clin Exp Med       Date:  2015-12-15

Review 10.  Treatment options for hyponatremia in heart failure.

Authors:  Steven R Goldsmith
Journal:  Heart Fail Rev       Date:  2008-09-06       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.